According to Xencor's latest financial reports the company's current revenue (TTM) is $0.16 B. In 2022 the company made a revenue of $0.16 B a decrease over the years 2021 revenue that were of $0.27 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.16 B | 2.28% |
2022 | $0.16 B | -40.18% |
2021 | $0.27 B | 124.22% |
2020 | $0.12 B | -21.7% |
2019 | $0.15 B | 285.93% |
2018 | $40.6 M | 50.72% |
2017 | $26.94 M | -69.22% |
2016 | $87.52 M | 215.25% |
2015 | $27.76 M | 191.62% |
2014 | $9.52 M | -6.41% |
2013 | $10.17 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 55,159.06% | ๐บ๐ธ USA |
AbbVie ABBV | $54.31 B | 32,167.22% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 16,646.07% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 35,610.30% | ๐บ๐ธ USA |
Seagen
SGEN | $2.30 B | 1,266.51% | ๐บ๐ธ USA |
MacroGenics MGNX | $56.91 M | -66.19% | ๐บ๐ธ USA |